The study of phenotypic and genetic intratumor heterogeneity in glioblastoma is attracting a lot of attention. Recent studies have demonstrated that transcriptional profiling analysis can help interpret the complexity of this disease. Previously proposed molecular classifiers have been recently challenged due to the unexpected degree of intratumor heterogeneity that has been described spatially and at single cell level. Different computational methods have been employed to analyze this huge amount of data, but new experimental designs including multisampling from individual patients and single-cell experiments require new specific approaches. In light of these results, there is hope that integration of genetic, phenotypic and transcriptional data coupled with functional experiments might help define new therapeutic strategies and classify patients according to key pathways and molecular targets that can be further investigated to develop personalized and combinatorial treatment strategies.
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Intratumor heterogeneity in glioblastoma
Glioblastoma (GBM) is the commonest brain tumor in adults and is characterized by a high degree of heterogeneity both at cellular and molecular level [34, 35] . At clinical presentation it can be classified either as primary or secondary with the former being characterized by absence of clinical or histological evidences of a less malignant tumor and the latter being the result of progression from a low-grade glioma [36] .
Historically, primary and secondary GBMs have been considered conceptually different but from a clinical and histopathological perspective they remain largely identical [36] . In the last decade, it has become increasingly clear that primary and secondary GBMs represent different entities characterized by distinct genetic pathways. In this text we refer to primary GBM unless specified
otherwise; yet, here we summarize the genetic alterations and pathways involved in the development of both primary and secondary GBMs as a service to the readers.
Primary and secondary GBMs show genetic alterations that are significantly different in frequency:
LOH 10q is frequent in both primary and secondary GBMs, whereas epidermal growth factor receptor (EGFR) amplification, p16
INK4a deletion and phosphatase and tensin homolog (PTEN) mutations are more frequent in primary GBMs. Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 10% of all GBMs [37] and are enriched in secondary GBMs [38] . p53 mutations are early common genetic events in secondary GBMs [36] but are present also in approximately 30% of primary GBMs. Despite this, more than 70% of primary GBMs show alterations in the p53
pathway [35] .
In addition to the amplification of EGFR (present in almost 50% of GBM [39] [40] [41] ) and the presence of extrachromosomal double minutes copies of this gene [42] , EGFR amplicons are often mutated in several variants. Among these, the most common is a deletion of exon 2-7 which generates a 4 truncated receptor that is unable to bind its ligand and is constitutively active (EGFRvIII) [36] .
Amplification of EGFR is frequently associated with deletion of the INK4a/Arf gene locus that encodes two tumor suppressors, p16 INK4a and p19 Arf (p14 Arf in humans), translated from alternatively spliced mRNAs [43] . p16 INK4a prevents the formation of the complex between cyclindependent kinase 4 (CDK4) and cyclin D1, thus preventing G1 entry [44] , while p19 Arf stabilizes p53 through binding to mouse double minute 2 homolog (MDM2).
The handling of GBM is challenging due to the heterogeneous nature of the disease, invasive potential and poor response to chemo-and radio-therapy. Median life expectancy in optimally managed patients is only 17-62 weeks with only 25% surviving 2 years [45] . The current clinical management of patients diagnosed with a GBM involves a combination of surgery, radiotherapy and chemotherapy. Radiotherapy has been the principal therapeutic modality since the late 1970s and the addition of targeted chemotherapy has only provided modest benefit [45, 46] .
The term 'multiforme' that is commonly used to describe GBM clearly summarizes the various morphological characteristics of the tissue and of the cell populations showing heterogeneous tracts in their phenotype and genotype [47] . Despite extensive brain tumor biology studies, the definitive identification of the cell type(s) that contribute to tumor growth has yet to come [48] . This is extremely relevant in order to provide insights into the cellular target(s) of the initial mutational events and to dissect the phenotypic heterogeneity emerging as a result of tumor growth.
Evidences from the cancer stem cell (CSC) hypothesis suggest that tumors hijack the functional properties of somatic stem cells and phenotypic heterogeneity is the result of a hierarchical organization of the tumor with its cell population showing various degrees of tumorigenic 5 potential regardless of their genotype and epigenetic status [49] . However, the CSC hypothesis does not address the issue of cell of origin [50] . More importantly, the lack of identification of cellular targets and the phenotypic complexity of the disease at the time of clinical presentation have hampered the development of innovative therapeutic approaches aimed at improving patient survival.
Spatial and temporal genetic intratumor heterogeneity in glioblastoma
The most extensive and well-characterized type of heterogeneity in GBM occurs at the genetic level. Initial studies in the 1980s revealed intratumor heterogeneity in GBM tissues and cells [51, 52] and were complemented by more sophisticated analyses using comparative genomic hybridization and laser scanning cytometry of microdissected GBM tissues [53, 54] . Seminal molecular studies in the 1990s shed light on the genetic heterogeneity across all glioma grades [55] [56] [57] and identified critical alterations in pathways that were mutually exclusive in GBM (CDKN2A (p16 INK4A , MTS1) and CDK4 versus RB) suggesting genetic heterogeneity among patients [58, 59] .
In the last years, large-screening data have elucidated the role of key signaling pathways in GBM by performing comprehensive analysis and integrating genomic, epigenomic and transcriptional data [60] [61] [62] . Focal somatic copy-number alterations found in The Cancer Genome [65] who showed that EGFR phosphorylates the mutant variant vIII and causes its nuclear translocation. In the nucleus, EGFRvIII forms a nuclear complex with STAT3 and is able to drive transformation [65] . The coexpression of EGFR wild type and vIII drives the phosphorylation of STAT in vitro and in vivo and enhances tumorigenicity providing further insights into the oncogenic cooperation among variants of the same genetic lesion. A more recent study has suggested that an additional mechanism involving the activation of MET operates between EGFR wild type and vIII [66] . All multiple somatic events and the heterogeneous expression of EGFR and its variants in GBM have been comprehensively resolved at single-cell level [67] . Mutations in a single RTK, like EGFR, contribute to enhance clonal diversification which further expands upon the recent observation of intratumor heterogeneity of multiple concurrent RTK amplifications [10, 13] .
Most recent studies have revealed spatial and temporal intratumor heterogeneity [5, 8, 26] . Using a fluorescence-guided resection method based on 5-ALA [68, 69] we have been able to 7 dissect distinct regions of the same GBM, starting from the residual disease (margin) that is left behind during surgery [68] to the resected disease (tumor mass) [8] . This has allowed us to describe the clonal evolutionary trajectories of GBM development and to show that EGFR amplification and CDKN2A/B/p14ARF deletion represent early events whereas PDGFRA amplification and PTEN deletion emerge later during GBM evolution.
An even more interesting observation of spatial intratumor heterogeneity came from the histological and genomic analysis of the subependymal zone (SEZ), the most well characterized neurogenic region of the human brain. Our recent study revealed that this region contributes to the genetic intratumor heterogeneity of GBM and is characterized by patterns of drug response that differ from the tumor mass [5] . Phylogenetic reconstruction showed different GBM evolution patterns in the analyzed patients where tumor cells from the SEZ correspond to clones that are generated early during tumor growth [5] , in agreement with what proposed in mouse model studies [70] [71] [72] [73] [74] [75] .
The use of patient-derived xenografts (PDX) has become increasingly popular in recent years, as they are believed to faithfully mimic the original human disease. In GBM, it has been shown that the 'avatar' model based on PDX recapitulates the pathological and genomic features of the original tumor and can be used to identify key regulatory signatures of clinical aggressiveness in patients [76] and to test novel therapeutic agents [77] . Very recently, we have exploited this model to reveal the genetic complexity during GBM evolution by identifying the clones that possess the tumor-initiating capacity and are able to transfer the disease to immunosuppressed animals [26] . This study represents an initial step into the complexity of GBM temporal evolution that is further complicated by the influence of the tumor microenvironment and the application of radical treatments, i.e. chemotherapy and radiotherapy, which impact on the clonal architecture 8 of the tumor. There are many examples of drug resistance conferred by the emergence of subclones harbouring specific somatic mutations [78] that might be therapy-driven.
This has been proven true for GBM that arises as a result of progression from a low-grade disease [19] but evidences in primary GBM are yet to come.
The influence of epigenetics
The most challenging type of heterogeneity occurs at the environmental level as this is extrinsically dynamic and multifactorial depending on different types of stromal cells, their interactions and different niches types (vascular, hypoxic, etc.) [79, 80] . The cellular microenvironment impacts the epigenetic status of a cell and the downstream epigenetic marks (methylation of cytosine nucleotides, histone protein modifications, chromatin remodeling complexes and noncoding RNA interference) will influence the transcriptional potential of the cell.
Genomic hyper-and hypomethylation has been shown in many cancer types and is associated to tumor formation and progression. As DNA methylation occurs primarily at CG dinucleotides in mammals, many cancer studies have targeted CG-rich regions and analyzed their aberrant 'methylomes' [81] [82] [83] . However, in recent years, non-CpG methylation has been found to regulate gene expression in embryonic stem cells and new research has focused on analysing the distribution and regulation of non-CpG methylation traits [84] [85] [86] . Genomic methylation patterns can vary among individual cells within the same tissue and are subject to dynamic changes during development [87, 88] . This epigenetic heterogeneity has also been described within tumors where only a subset of aberrant DNA methylation events are recurrently found across different tumor regions [89] [90] [91] .
In patients with GBM the oral alkylating agent temozolomide is the current standard of 9 care. This drug is more effective on tumors where there is epigenetic silencing of the O-6-methylguanine-DNA methyltransferase (MGMT) gene encoding a methyltransferase that inhibits the cytotoxic effect of temozolomide. Two regions in the MGMT promoter have been recently identified as critical for transcriptional silencing and prediction of the response to alkylating agents [92] . Interestingly, hypermethylation of the MGMT promoter has been observed in all the subtypes of the Verhaak classification [34] . Recently, we have shown that MGMT methylation status seems to be quite homogeneous in different GBM tumor areas [8] and generally predicts response to temozolomide [5] . Notwithstanding, beneficial response to this drug has also been seen in MGMT-unmethylated tumors, which suggests that MGMT methylation changes over time [93] and is influenced by treatment [94] reflecting a temporal rather than spatial heterogeneous status.
Several groups have described additional promoter hypermethylation in GBM, often influencing the expression of GBM tumor suppressor genes like PTEN and P53, as well as of regulatory genes involved in cell proliferation, invasion and cytokine signaling [95] . Also the expression of EGFRvIII has been shown to be epigenetically modulated through methylation and hystone acetylation [96] .
Epigenomic profiling in GBM has revealed a distinct subgroup called glioma CpG island methylator phenotype (G-CIMP) [97] that is enriched for the proneural expression group. If analyzed in the context of the proneural subtype, the G-CIMP group is clinically characterized by longer survival and it is associated with IDH1 mutations [95, 97] . Interestingly, the MGMT promoter methylation is independent from the CpG island methylator phenotype.
These findings were followed by a comprehensive epigenetic and biological classification of pediatric and adult GBM [98] that defined six GBM subtypes based on global DNA methylation patterns, IDH1 mutations and two mutations in aminoacids K27 and G34 of the histone variant 10 H3.3. Interestingly, the authors found that the anatomical localization of K27 and G34 mutant tumors was different (midline locations and embryonic regions of neocortex and striatum, respectively) and that these mutations occurred mainly in pediatric GBM [98] . The molecular mechanisms underlying the transcriptional signature of K27 mutant tumors were described in a subsequent study showing that the reduction of K27 trimethylation on histone H3 interferes with the enzymatic activity of histone methyltransferase EZH2. This causes alterations in H3K27me3 occupancy at the transcription start site of promoters across the whole genome of K27 mutant tumors. As a result, a pronounced global DNA hypomethylation resetting drives the emergence of a K27 mutant-specific gene expression profile [99] .
Epigenetic modulators are currently being targeted as druggable candidates in several cancers.
Epigenetic therapy has been applied with reasonable success in hematologic malignancies using DNA methyltransferase (decitabine, 5-azacitidine) and histone deacetylase inhibitors (vorinostat, romidepsin). In contrast, relatively low efficacies have been achieved on solid tumors; this is likely due to their intrinsic heterogeneous nature which allows tumors to develop treatment resistance [100] . A fundamental characteristic of epigenetics is that the same genomic sequence can show alternative phenotypes by reprogramming gene expression. Thus, intratumor heterogeneity at the epigenetic level will be reflected into transcriptional variability within tumors which will affect its evolutionary potential and is of vital importance on future clinical decision making.
Transcriptional analysis
In a critical review of the pathology of cerebral gliomas in 1940, Scherer H.J. described that primary GBMs are constituted of at least two or more "distinct pathological entities" [101] .
Transcriptional analysis in GBM has been extensively used with the aim to dissect the phenotypic In an initial study including all grades of astrocytic tumors, an artificial neural network algorithm was developed to define survival prognostic subtypes [109] (denoted ANGIO, INTER, and LOWER) that had a perfect correspondence with the histological grade of these tumors.
More recently, several groups have focused on developing accurate molecular prognostic classification systems to specifically stratify GBM patients. To this aim, large cohort genome-wide profiling analyses [110] [111] [112] The clinical relevance of this classification relies on its association to survival and response to treatment that differs among subtypes: the Proneural subtype is associated with a trend toward longer survival but the better response to treatment is observed in the Classical subtype [110] .
More recently, a different approach based on gene co-expression modules of key pathways, such as EGFR and PDGFR, has been explored to develop a clinically relevant classifier for both adult lowgrade and high-grade gliomas [114] .
However, in the last years it became clear that given the extensive spatial genetic intratumor heterogeneity in GBM it is difficult to make sense of these data based on a single GBM sample per patient (Fig.1) . Also, such classification does not segregate all the GBM key aberrations, in fact some are found in more than one subtype, in other words CDKN2A and CDKN2B, and are shared with low-grade gliomas [34] suggesting that they are essential for the stepwise malignant growth.
More recently, transcriptome sequencing has been employed to reveal gene fusions in GBM [61] some of which occur in noncoding genes, resulting in the expression of noncoding RNAs that are not expressed in normal cells [115] . 13 In colorectal cancer, single-cell PCR gene expression analysis has been used to dissect the cellular composition of normal and cancer tissue [116] . In GBM, single-cell transcriptome analysis by RNA sequencing has revealed extensive intratumor heterogeneity and a "stem celldifferentiation gradient" that is not fully recapitulated in in vitro models [27] . More importantly, single-cell analysis has confirmed that more than one sub-type coexists in the same tumor as previously reported [8] (Fig.1) and suggested that hybrid phenotypic states reminiscent of progenitor and differentiated cells are present in individual cells of the same GBM [27] . These data highlight the dynamics of cellular states in GBM that can have implications for developing new therapeutic approaches. An example of this dynamic regulation has been recently provided in a study about extrachromosomal EGFRvIII showing that GBM cells suppress the expression of EGFRvIII following treatment with tyrosine kinase inhibitors but is upregulated after drug removal [117] .
In the last decade, thousands of computational methods and bioinformatics tools have been developed to analyze gene expression patterns initially derived from gene expression microarray measurements and more recently from RNA-sequencing data. Most of these bioinformatics tools have used empirical Bayes methods [118] [119] [120] or estimates of the mean and variance [121, 122] to analyze differential expression levels. These tools have been applied to quantify transcription levels among single biopsies from several cancer patients or between cancer patients and controls.
New studies that consider the variability in intratumor expression levels include multiple samples from a single patient and/or multiple single cells from the same tumor. These studies aim at gaining a better understanding of regional and temporal transcriptional profiles within a tumor.
However, new dependencies emerge from the measurements (mRNA expression levels for each In this study, the authors found differential expression levels between three spatially separated regions of GBM tumors: the tumor mass, the SEZ and the tumor margin [5, 68] . Furthermore, when genes were classified into one of the Gene Ontology biological 15 processes they found marked functional heterogeneity as most of the analyzed groups harbor differentially expressed genes.
Computational approaches that allow integration of transcriptomic, genomic and epigenomic data will be key to achieve a comprehensive understanding of intratumor heterogeneity. These methods will lead to new 'heterogeneity signatures' that will aid with clinical decision making to apply individualised treatments to cancer patients.
Conclusion
Intratumor heterogeneity highlights the complexity of tumor genomic landscape and may present major challenges to biomarker identification and overcoming treatment resistance. The existence of treatment resistant clones and the influence of microenvironment favour tumor relapse. In GBM initial insights into clonal distribution [5, 8, 26, 27] and cooperativity among EGFR variants [65, 124] have shed new light into the mechanisms underlying tumor heterogeneity. At trascriptional level, recent studies have shown a previously unrecognised heterogeneous profile in distinct region of the same GBMs as well as at single-cell level [5, 8, 27] (Fig. 1) . These findings support the concept that a detailed molecular inter-and intra-patient analysis is needed to develop personalized therapies and eventually target regions of the same GBM with different therapeutic approaches.
By comparing the SEZ and the tumor mass of the same patient, we have observed differential pattern of response to the standard treatment based on the alkylating agent temozolomide, cisplatin and cediranib [5] . Similar analyses on primary cells derived from different regions of the same GBM might inform therapeutic decision.
Molecular tumor subtypes identified through transcriptional analysis have been proposed to be 16 clinically relevant and important for prognostic value, however these classifications did not take into account sample heterogeneity. Analysis of primary tumor cells and single-cell technologies might help refining the existing GBM subtype classification and improving patient stratification.
Unfortunately, there is currently no approved therapy besides the Stupp protocol [45, 46] , thus clinicians have no alternatives to offer after exhausting the traditional treatments (surgery, radiation, alkylating chemotherapy and eventually anti-angiogenetic therapy).
Hence, performing exhaustive genetic, transcriptomic and epigenetic testing seem invaluable to provide insights into more personalized treatments and/or further therapeutic alternatives for GBM patients. Nevertheless, these molecular-based tests are certainly time consuming and the integration of the data is not trivial which makes the interpretation of the results quite complex.
Future perspective
With the emergence of next-generation sequencing technologies, we have changed our understanding of tumor heterogeneity. These technologies have revealed an unexpected molecular complexity from bulk population to single-cell level and have challenged the way by which we think of cancer development and treatment.
GBM is a remarkable example of a phenotypic and genetic heterogeneous tumor and despite the challenges associated with improving current treatments, there is hope that the integration of accurate data reflecting the genetic, transcriptional and epigenetic intratumor heterogeneity in addition to functional studies may lead to the definitive identification of tumor drivers and druggable therapeutic targets (Fig. 2) .
Executive summary
 Glioblastoma (GBM) is the most common and aggressive brain cancer in adults.
 The prognosis of GBM remains dismal despite the current treatments based on surgical resection and combination of chemo-and radio-therapy.  Bioinformatics tools that allow integration of transcriptomic, genomic and epigenetic data will be key to achieve a comprehensive understanding of intratumor heterogeneity that will lead to better classification of patients and aid to define novel therapeutic strategies important for clinical decision making.
Conclusion
 Transcriptional profiling needs to be further investigated in light of recent data of intratumor heterogeneity in GBM.
 A comprehensive analysis of distinct tumor areas and single cells can shed new light on the molecular mechanisms sustaining tumor growth and develop more refined molecular 18 classifiers of GBM patients.
Future perspective
 Integration of genetic, phenotypic and transcriptional data with functional experiments can help design new molecular patient-specific therapeutic approaches. shown consistently with Sottoriva&Spiteri and colleagues [8] ) or at single-cell level (430 cells/GBM as described by Patel and colleagues [27] ). The data generated by these 3 different approaches can be used to investigate intra-tumor heterogeneity at transcriptional level and potentially gain new insights into GBM biology and prognosis. By applying a previously published classifier, the multi-sampling scheme and single-cell analysis have revealed that multiple subtypes coexist in the same tumor with implications for patients stratification and response to standard therapy.
Figure legends
Pron=Proneural, Mes= Mesenchymal, Cla= Classical. 
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